SurModics (SRDX) Tops Q1 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
SurModics Reports First Quarter Fiscal 2016 Results
January 28, 2016 7:35 AM ESTGAAP Revenue of $16.5 Million, up 16% GAAP EPS of $0.19, Non-GAAP EPS of $0.38 Fiscal 2016 Guidance Reaffirmed
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2016 first quarter, ended December 31, 2015.
The SurModics team had an exceptional first quarter of fiscal 2016, said Gary Maharaj, president and chief executive officer. We delivered outstanding results from our core Medical Device and In Vitro Diagnostic... More
